GABA Therapeutics is conducting Phase 1 studies in Australia for the following reasons:

  1. Australian law allows clinical studies to commence before an IND is submitted, substantially expediting the program, and
  2. Current Australian tax law provides for a 43.5% tax rebate on eligible clinical related costs.